Changing Jobs or Health Plans With IBD: A Medication-Continuity Checklist

A job change is a scheduling problem before it is a benefits problem. If you take an infusion every eight weeks or a self-injection on a fixed date, the calendar that matters is not your start date at the new employer but the date of your next dose and the date your current plan stops paying for it. Inflammatory bowel disease (IBD) treatment depends on a chain of approvals that includes the plan, the prescriber, the specialty pharmacy or infusion center, and often a manufacturer copay program. Every link in that chain resets when your coverage changes. Working through a job change as a medication continuity checklist, ordered around the change date rather than around your first day, keeps the chain intact.

Start With Your Dosing Calendar, Not Your Enrollment Form

Before comparing plans, write down the next three dose dates and the date your current coverage terminates. Maintenance biologic schedules are fixed and unforgiving. Infliximab, for example, is labeled for a maintenance regimen of 5 mg/kg every 8 weeks after induction in Crohn's disease, so a four-week administrative delay is half an interval. Delay is already the norm without a coverage change: in a Canadian cohort, 92.1% of patients had at least one delayed maintenance infliximab infusion, with a mean delay of 3.3 days per infusion. The practical move is to ask your gastroenterologist whether a dose can be pulled forward to land safely inside the old plan's coverage window, giving you a full interval of runway to complete enrollment and reauthorization under the new plan.

COBRA and Marketplace Coverage Solve Different Problems

Two bridges exist between plans, and they behave differently. Under federal law you have an election period of at least 60 days to choose COBRA continuation coverage, and the plan may not require your first premium payment before the 45th day after you elect. Because COBRA is retroactive to the date coverage was lost, that structure lets you keep the option open without paying immediately, which is valuable when a new employer's coverage may start soon. Continuation generally runs up to 18 months after a termination or reduction in hours, and the plan may charge up to 102% of the applicable premium.

COBRA's advantage for IBD is continuity of the exact plan, network, formulary tier, and existing prior authorization. Its disadvantage is cost, since you absorb the employer's contribution.

Marketplace Timing Runs on Its Own Clock

Losing job-based coverage triggers a special enrollment period. Federal rules give you 60 days before and 60 days after the triggering event to select a qualified health plan, and if you make the selection on or before the day coverage ends, the exchange must set the effective date as the first day of the following month. HealthCare.gov states the same consumer-facing deadline, that you can enroll in a Marketplace plan within 60 days of losing your job-based coverage, and notes that switching from COBRA to a Marketplace plan outside open enrollment is allowed when COBRA is running out or the former employer stops contributing. Marketplace subsidies depend on household income rather than employment status, so premium tax credits are worth checking even if you expect to work again soon. Selecting early matters more than selecting cheaply, because a mid-month effective date gap is exactly where a dose falls through.

What a New Employer Plan Can and Cannot Do

A new group plan cannot exclude your IBD. Federal rules bar group health plans and issuers from imposing any preexisting condition exclusion. A plan also cannot make you wait indefinitely, since it must not apply any waiting period that exceeds 90 days. Ninety days is still more than one infliximab interval, so confirm the exact waiting period in writing during the offer stage rather than at orientation.

If your spouse has employer coverage, losing your own coverage opens a window there too. Group plans must allow at least 30 days after the loss of other coverage to request special enrollment. That window is shorter than the Marketplace's 60 days and is easy to miss while a job transition is consuming your attention.

Rebuild Prior Authorization Before the Switch Date

A new plan means a new prior authorization, a new specialty pharmacy relationship, and possibly a new step therapy requirement even for a drug you have taken for years. The cost of that reset is measurable. In a study of 190 pediatric IBD patients, prior authorization added 10.2 days to biologic initiation and 24.6 days when the authorization was complicated by appeals or step therapy, and was associated with a 12.9% increase in the likelihood of hospitalization, surgery, or an emergency visit within 180 days. Among 220 adults, median time from a dose escalation decision to insurance approval was 7 days, rising to 29 days when an appeal was required, and longer approval times were associated with lower odds of C-reactive protein improvement. Ask your clinic to submit the new authorization the day the new plan's member ID exists, and send the documentation package that already worked: notes, prior therapy history, and lab or endoscopy findings.

Protect the Specialist and Infusion Site, Then Watch the First 90 Days

Networks change even when the drug does not. Verify that your gastroenterologist, the infusion center, and the specialty pharmacy are all in network under the specific plan variant you are choosing, since a health system can be contracted while an affiliated infusion suite is not. If a provider's contract is terminated while you are in active treatment, federal law gives continuing care patients a 90-day transitional care period at in-network terms. For Medicare drug coverage, a parallel protection applies to formulary friction: Part D plans must provide a temporary supply of at least a month for drugs that require prior authorization or step therapy during the first 90 days of coverage under a new plan. Commercial plans are not bound by that rule, which is why the commercial transition depends on your own sequencing rather than on a statutory safety net. Once the first dose clears under the new plan, confirm in writing what was approved, for how many doses, and through which pharmacy, so the next renewal starts from a documented baseline instead of a phone call.